Trastuzumab for the Treatment of Salivary Duct Carcinoma
Sewanti Limaye(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Deborah Dillon(Harvard University), Roy B. Tishler(Dana-Farber Cancer Institute), Jeffrey F. Krane(University of California, Los Angeles), Aditya Shreenivas(City Of Hope National Medical Center), Jochen H. Lorch(Northwestern University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), María Fonfría(Harvard University)
Cited by 185
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926